## COUNTRY GENERAL INFORMATION (WHO, 2015)

- **Total population:** 31,540,000
- **Gender F/M (%):** 42.5 / 57.5
- **Population, age group <15/≥15 years (%):** 29 / 71
- **Life expectancy at birth (F/M, years) (2015):** 76 / 73
- **GDP (PPP int $):** 53,780
- **Income status:** High
- **Number of 1st sub-national administrative level divisions, name:** 13, Region

### EPIDEMIOLOGY

<table>
<thead>
<tr>
<th>Endemicity status</th>
<th>VL</th>
<th>ACL</th>
<th>ZCL</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endemic</td>
<td>4</td>
<td>234</td>
<td>1,256</td>
<td>N/A</td>
</tr>
<tr>
<td>Endemic</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>Non endemic</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
</tbody>
</table>

- **Number of new cases (incidence):**
  - VL: 4
  - ACL: 234
  - ZCL: 1,256
  - MCL: N/A

- **Number of relapses:**
  - VL: 0
  - ACL: 0
  - ZCL: 0
  - MCL: N/A

- **Total number of cases:**
  - VL: 4
  - ACL: 234
  - ZCL: 1,256
  - MCL: N/A

- **Imported cases [# (%):**
  - VL: 1.25%
  - ACL: 0.0%
  - ZCL: 0.0%
  - MCL: No data

- **Gender distribution [% F]:**
  - VL: 50%
  - ACL: 35%
  - ZCL: 20%
  - MCL: N/A

- **Age group distribution [% <15/15+/≥14]:**
  - VL: (75/0/25)
  - ACL: (10/33/57)
  - ZCL: (7/14/79)
  - MCL: N/A

- **Incidence rate (cases/10,000 population in endemic areas):**
  - VL: 0.65
  - ACL: 0.45
  - ZCL: N/A
  - MCL: N/A

- **Number of endemic 1st sub-national administrative level divisions:**
  - VL: 5
  - ACL: 3
  - ZCL: 17
  - MCL: N/A

- **Population at risk [% # at risk/total population]:**
  - VL: 30% 9,434,776/31,540,000
  - ACL: 11% 3,590,391/31,540,000
  - ZCL: 89% 28,097,507/31,540,000
  - MCL: N/A

- **Was there any outbreak?**
  - VL: No
  - ACL: No
  - ZCL: No
  - MCL: N/A

- **Number of new foci:**
  - VL: 0
  - ACL: 0
  - ZCL: 0
  - MCL: No data

N/A = Not applicable; 1 Relapse in this country is defined as: “Reappearance of symptoms and clinical signs after cure”; 2 Defined as: “Number of people living in 1st sub-national endemic areas”;

### Monthly distribution of new cases (January-December)

<table>
<thead>
<tr>
<th>Year</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>VL</td>
<td>ACL</td>
<td>ZCL</td>
<td>ACL</td>
<td>ZCL</td>
<td>ACL</td>
<td>ZCL</td>
<td>ACL</td>
<td>ZCL</td>
<td>ACL</td>
<td>ZCL</td>
<td>ACL</td>
</tr>
<tr>
<td>2015</td>
<td>1</td>
<td>33</td>
<td>266</td>
<td>33</td>
<td>266</td>
<td>33</td>
<td>266</td>
<td>33</td>
<td>266</td>
<td>33</td>
<td>266</td>
<td>33</td>
</tr>
</tbody>
</table>

VL = visceral leishmaniasis; ACL = anthropoctic cutaneous leishmaniasis; ZCL= zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

---

**Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015**
### Disease distribution of new VL and CL cases at region level per 10,000 population (2015)

#### Visceral leishmaniasis

- **Visceral leishmaniasis (VL)**
- **Cutaneous leishmaniasis (CL)**

#### CONTROL AND SURVEILLANCE

**Year Leishmaniasis National Control Programme (LNCP) was established:** 1983

**Type of surveillance:** Integrated

**Is there a vector control programme?** Yes

**Type of insecticide used for Indoor residual Spraying (IRS):** Deltamethrin

**Year latest national guidelines:** 2000

**Is leishmaniasis notifiable (mandatory report)?** Yes

**Is there a reservoir host control programme?** No

**Number of leishmaniasis health facilities:** 249

#### DIAGNOSIS

**Number of people screened actively for:** No data

**Number of people screened passively for:** No data

**Cases diagnosed by RDT* (%, # RDT+/ total VL cases):** 100% (4/4)

**Proportion of positive RDT* (%, # RDT+/total RDT):** 100% (4/4)

**Cases diagnosed by direct exam* (parasitology) (%, # slides + / total cases):** 100% (4/4)

**Proportion of positive slides* (%, # slides + / total slides):** 100% (4/4)

**Cases diagnosed clinically* (%, # clinical cases/ total cases):** 0% (0/4)

**Proportion of CL cases with lesions equal to or greater than 4cm*:** N/A

**Proportion of CL cases with 4 or more lesions*:** N/A

**Percentage of cases with HIV coinfection*:** 0% (0/4)

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

#### TREATMENT AND MEDICINES

- Is treatment provided for free in the public sector? Yes
- Antileishmanial medicines included in the National Medicine List: Sodium stilbogluconate (SSG), Liposomal amphotericin B

#### TREATMENT OUTCOME

<table>
<thead>
<tr>
<th>VL</th>
<th>ACL</th>
<th>ZCL</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of cases treated* (%, # treated cases/ total cases):</td>
<td>100% (4/4)</td>
<td>100% (234/234)</td>
<td>100% (1,256/1,256)</td>
</tr>
<tr>
<td>Initial cure rate* (%, # cases initially cured / total cases):</td>
<td>100% (4/4)</td>
<td>100% (234/234)</td>
<td>100% (1,256/1,256)</td>
</tr>
<tr>
<td>Failure rate** (%, # patients with treatment failure / total cases):</td>
<td>0% (0/4)</td>
<td>0% (0/234)</td>
<td>0% (0/1,256)</td>
</tr>
<tr>
<td>Case fatality rate* (%, # patients who died/ total cases):</td>
<td>0% (0/4)</td>
<td>0% (0/234)</td>
<td>0% (0/1,256)</td>
</tr>
</tbody>
</table>

**VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

* Failure in this country is defined as: "Deterioration or no improvement during the treatment period"

** These indicators only apply to new cases